A carregar...
Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
Allogeneic hematopoietic cell transplantation (allo HCT) remains a valuable alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on allo HCT outcomes in the era of new HL therapies are needed. We evaluated 72 R/R HL patients who received reduced intensity conditioning (RIC) allo HCT...
Na minha lista:
| Publicado no: | Bone Marrow Transplant |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5415418/ https://ncbi.nlm.nih.gov/pubmed/28134921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2016.357 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|